Physician profile
Mohammad Mousa
NPI 1841383221
$3,043.79
in general payments reported to CMS, 2019-2025
34 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $261 · 2021: $26.19 · 2022: $482 · 2023: $712 · 2024: $517 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Education: $80.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.08 |
| Education | $80.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $649.41 | 2022-2024 | |
| Corcept Therapeutics | $413.39 | 2019-2025 | Korlym |
| Acadia Pharmaceuticals INC | $325.36 | 2019-2025 | Nuplazid |
| Astrazeneca Pharmaceuticals Lp | $173.09 | 2019-2020 | |
| Lilly USA, LLC | $153.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $128.52 | 2022-2025 | Tepezza |
| Medtronic Minimed, INC. | $106.61 | 2020 | |
| Xeris Pharmaceuticals, INC. | $88.90 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $83.06 | 2021-2025 | Omnipod |
| Ibsa Pharma INC. | $81.69 | 2024-2025 | Licart, Tirosint, Flector |
| Medtronic, INC. | $81.61 | 2022-2023 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.94 | 2019-2024 | Synjardy, Jardiance |
| Beta Bionics, INC. | $66.84 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Horizon Therapeutics Plc | $56.64 | 2023 | Tepezza |
| Abbott Laboratories | $53.42 | 2024-2025 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $51.47 | 2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $50.48 | 2024-2025 | Ingrezza |
| Abbvie INC. | $45.41 | 2023-2024 | |
| Evoke Pharma, INC. | $41.71 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $32.68 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $32.50 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $25.62 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $24.18 | 2023 | Aptiom |
| Kyowa Kirin, INC. | $22.66 | 2023 | Crysvita |
| Lundbeck LLC | $22.57 | 2023 | Rexulti |
| Novo Nordisk INC | $22.45 | 2023 | Wegovy |
| Soleno Therapeutics, INC. | $22.19 | 2025 | Vykat Xr |
| Sequel Med Tech, LLC | $18.32 | 2025 | Twiist |
| Acella Pharmaceuticals, LLC | $18.16 | 2025 | NP Thyroid 60 |
| Teva Pharmaceuticals USA, INC. | $17.66 | 2024 | Austedo Xr |
| Astellas Pharma US INC | $15.75 | 2025 | Veozah |
| Nevro Corp. | $15.61 | 2023 | Senza |
| Ascendis Pharma Endocrinology INC | $15.56 | 2025 | Yorvipath |
| Urovant Sciences INC | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Mousa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.